Stock BMYS BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Bristol-Myers Squibb Company Wiener Boerse

Equities

BMYS

US1101221083

Real-time Estimate Tradegate
Other stock markets
 02:04:03 04/07/2024 pm IST 		5-day change 1st Jan Change
37.48 EUR -4.60% Intraday chart for Bristol-Myers Squibb Company -1.39% -15.25%
02/07 Cartesian Therapeutics, Inc. Appoints Kemal Malik to its Board of Directors CI
01/07 Bristol-Myers Squibb to Pay $2.7 Million to Settle Potential Anti-Competition Case, Israeli Agency Says MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The company returns high margins, thereby supporting business profitability.
  • The company has a low valuation given the cash flows generated by its activity.
  • The company is one of the best yield companies with high dividend expectations.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • The company appears highly valued given the size of its balance sheet.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
BRISTOL-MYERS SQUIBB COMPANY Stock Bristol-Myers Squibb Company
-15.25% 81.21B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+54.07% 809B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+37.82% 621B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.05% 351B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.44% 319B
B-
ABBVIE INC. Stock AbbVie Inc.
+5.72% 289B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.04% 238B
B+
ROCHE HOLDING AG Stock Roche Holding AG
-1.72% 221B
A+
NOVARTIS AG Stock Novartis AG
+13.84% 218B
B-
AMGEN INC. Stock Amgen Inc.
+7.42% 166B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. BMY Stock
  4. BMYS Stock
  5. Ratings Bristol-Myers Squibb Company